Literature DB >> 32082644

IVIG and under Burn Unit Care Yield Favorable Outcomes in Pediatric Patients with Toxic Epidermal Necrolysis: A Case Report and Literature Review.

Tareq Z Alzughayyar1, Wasim Noureddin Ibrahim Hamad1, Eman A S Abuqweider1, Bilal Nabeel Mohammad Alqam1, Sadi A Abukhalaf1, Rami A Misk2, Fawzy M Abunejma3, Jihad Samer Zalloum1, Mohanad Saleh4, Ali A Abumunshar2, Yousef I M Zatari2.   

Abstract

Body reactions to drugs can manifest as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). TEN is the most severe form of cutaneous reactions with an incidence rate of 1-2 per million cases per year. Despite TEN being a critical and life-threatening condition, there is little to no evidence of clear management protocol. We reported a 5-year-old male child who presented with lamotrigine-induced TEN and was successfully treated with intravenous immune globulin (IVIG) with a burn unit care level, while TEN treatment with IVIG is an appropriate approach with predictable good outcomes, burn unit care is also effective in creating highly favorable effects. Upon reviewing the literature, several studies indicate that TEN patients treated with the combination of IVIG and burn unit care lead to decreased levels of morbidity and mortality than when treated with IVIG or burn unit care alone. Therefore, treatment involving both IVIG and burn unit care should be considered for TEN patients.
Copyright © 2020 Tareq Z. Alzughayyar et al.

Entities:  

Year:  2020        PMID: 32082644      PMCID: PMC7013329          DOI: 10.1155/2020/6274053

Source DB:  PubMed          Journal:  Case Rep Dermatol Med        ISSN: 2090-6463


  26 in total

Review 1.  Toxic epidermal necrolysis (Lyell syndrome).

Authors:  J C Roujeau; O Chosidow; P Saiag; J C Guillaume
Journal:  J Am Acad Dermatol       Date:  1990-12       Impact factor: 11.527

Review 2.  Toxic epidermal necrolysis.

Authors:  Frederick A Pereira; Adarsh Vijay Mudgil; David M Rosmarin
Journal:  J Am Acad Dermatol       Date:  2007-02       Impact factor: 11.527

Review 3.  A systematic review of the management and outcome of toxic epidermal necrolysis treated in burns centres.

Authors:  Patrick D Mahar; Jason Wasiak; Belinda Hii; Heather Cleland; David A Watters; Douglas Gin; Anneliese B Spinks
Journal:  Burns       Date:  2014-03-27       Impact factor: 2.744

4.  Carbamazepine-induced Stevens-Johnson syndrome treated with IV steroids and IVIG.

Authors:  R Straussberg; L Harel; D Ben-Amitai; D Cohen; J Amir
Journal:  Pediatr Neurol       Date:  2000-03       Impact factor: 3.372

Review 5.  A recent update of pharmacogenomics in drug-induced severe skin reactions.

Authors:  Chun-Yu Wei; Tai-Ming Ko; Chen-Yang Shen; Yuan-Tsong Chen
Journal:  Drug Metab Pharmacokinet       Date:  2011-11-01       Impact factor: 3.614

Review 6.  Complications of Stevens-Johnson syndrome beyond the eye and skin.

Authors:  Hajirah Saeed; Iason S Mantagos; James Chodosh
Journal:  Burns       Date:  2015-04-09       Impact factor: 2.744

Review 7.  The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis.

Authors:  Y-C Huang; Y-C Li; T-J Chen
Journal:  Br J Dermatol       Date:  2012-08       Impact factor: 9.302

8.  Toxic epidermal necrolysis: an analysis of referral patterns and steroid usage.

Authors:  S L Engelhardt; M J Schurr; R B Helgerson
Journal:  J Burn Care Rehabil       Date:  1997 Nov-Dec

9.  Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience.

Authors:  M Stella; P Cassano; D Bollero; A Clemente; G Giorio
Journal:  Dermatology       Date:  2001       Impact factor: 5.366

10.  Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases.

Authors:  Christa Prins; Francisco A Kerdel; R Steven Padilla; Thomas Hunziker; Sergio Chimenti; Isabelle Viard; Davide N Mauri; Kirsten Flynn; Jennifer Trent; David J Margolis; Jean-Hilaire Saurat; Lars E French
Journal:  Arch Dermatol       Date:  2003-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.